Literature DB >> 19743997

En-bloc resection of multiple type 1 gastric carcinoid tumors by endoscopic multi-band mucosectomy.

Andrew D Hopper1, Michael J Bourke, Luke F Hourigan, Kayla Tran, Alan Moss, Michael P Swan.   

Abstract

BACKGROUND AND AIM: Gastric carcinoid tumors are rare but increasing in incidence. Current recommendations suggest endoscopic resection for type I carcinoids found in the stomach, however reports of incomplete resection have led to difficulty planning future management. Our purpose was to describe the application of the endoscopic multi-band mucosectomy (MBM) device to achieve en-bloc resection of multiple gastric carcinoid tumors.
METHODS: Over a 30-month period (June 2006-January 2009) eight patients attending for endoscopic assessment of gastric carcinoid tumors were identified at two tertiary referral centers. Patients underwent endoscopic resection of the carcinoids with an MBM device. En-bloc specimens underwent histological evaluation for identification and tumor resection margins. Patients with type I carcinoids were subsequently enrolled in an endoscopic follow-up program.
RESULTS: A total of 34 gastric carcinoid tumors were removed from eight patients. On histological analyses seven out of eight patients were diagnosed with type I tumors. In the remaining patient a single, sporadic (type III) gastric carcinoid was diagnosed. No complications of severe bleeding or perforation occurred. All specimens were shown to have clear deep and peripheral histological resection margins.
CONCLUSION: Complete 'en-bloc' endoscopic resection of multiple 'type I' gastric carcinoid tumors can be safely and easily performed with an MBM technique.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19743997     DOI: 10.1111/j.1440-1746.2009.05909.x

Source DB:  PubMed          Journal:  J Gastroenterol Hepatol        ISSN: 0815-9319            Impact factor:   4.029


  9 in total

1.  Long-term follow up of endoscopic resection for type 3 gastric NET.

Authors:  Yong Hwan Kwon; Seong Woo Jeon; Gwang Ha Kim; Jin Il Kim; Il-Kwun Chung; Sam Ryong Jee; Heung Up Kim; Geom Seog Seo; Gwang Ho Baik; Kee Don Choi; Jeong Seop Moon
Journal:  World J Gastroenterol       Date:  2013-12-14       Impact factor: 5.742

2.  Comparison of the clinical value of multi-band mucosectomy versus endoscopic mucosal resection for the treatment of patients with early-stage esophageal cancer.

Authors:  Zi-Yang Chen; Yun-Chao Yang; Li-Mei Liu; Xiao-Gang Liu; Y I Li; Liang-Ping Li; Xiao Hu; Ren-Yi Zhang; Yan Song; Qin Qin
Journal:  Oncol Lett       Date:  2015-04-02       Impact factor: 2.967

Review 3.  Somatostatin analogs for gastric carcinoids: For many, but not all.

Authors:  Sara Massironi; Alessandra Zilli; Dario Conte
Journal:  World J Gastroenterol       Date:  2015-06-14       Impact factor: 5.742

Review 4.  [Gastric neuroendocrine tumors. Endoscopic and surgical treatment].

Authors:  M B Niederle; B Niederle
Journal:  Chirurg       Date:  2011-07       Impact factor: 0.955

5.  Endoscopic submucosal dissection for foregut neuroendocrine tumors: an initial study.

Authors:  Quan-Lin Li; Yi-Qun Zhang; Wei-Feng Chen; Mei-Dong Xu; Yun-Shi Zhong; Li-Li Ma; Wen-Zheng Qin; Jian-Wei Hu; Ming-Yan Cai; Li-Qing Yao; Ping-Hong Zhou
Journal:  World J Gastroenterol       Date:  2012-10-28       Impact factor: 5.742

Review 6.  Comparison of Endoscopic Techniques in the Management of Type I Gastric Neuroendocrine Neoplasia: A Systematic Review.

Authors:  Francesco Panzuto; Ludovica Magi; Gianluca Esposito; Maria Rinzivillo; Bruno Annibale
Journal:  Gastroenterol Res Pract       Date:  2021-03-30       Impact factor: 2.260

7.  Clinical impact of endoscopic submucosal dissection for gastric neuroendocrine tumors: a retrospective study from mainland China.

Authors:  Wei-Feng Chen; Ping-Hong Zhou; Quan-Lin Li; Mei-Dong Xu; Li-Qing Yao
Journal:  ScientificWorldJournal       Date:  2012-12-23

Review 8.  Endoscopic treatment for early foregut neuroendocrine tumors.

Authors:  Moo In Park
Journal:  Clin Endosc       Date:  2013-09-30

9.  Netazepide, a gastrin receptor antagonist, normalises tumour biomarkers and causes regression of type 1 gastric neuroendocrine tumours in a nonrandomised trial of patients with chronic atrophic gastritis.

Authors:  Andrew R Moore; Malcolm Boyce; Islay A Steele; Fiona Campbell; Andrea Varro; D Mark Pritchard
Journal:  PLoS One       Date:  2013-10-01       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.